Revenue Recognition (Details) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended			6 Months Ended
	Mar. 31, 2023 USD ($) item	Aug. 31, 2019	Feb. 28, 2019 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2019 USD ($)
Allowances on accounts receivable									$ 1,300
Other assets				$ 29,311			$ 29,311		15,403
Deferred revenue				36,783	$ 37,146		36,783	$ 37,146	35,740	$ 30,778
Disruption at Change Healthcare
Allowances on accounts receivable				16,600			$ 16,600
Product
Approximate percentage of revenue collected within 9 months							90.00%
Billing collection period (in months)							9 months
Extended billing collection period (in months)							6 months
Increased (decreased) revenues				1,700	800		$ 3,800	6,500
(Increased) decreased net loss				$ 1,700	$ 800		$ 3,800	$ 6,500
(Increased) decreased net loss per share | $ / shares				$ 0.01	$ 0.01		$ 0.03	$ 0.06
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues				$ 39,900	$ 3,400		$ 73,700	$ (5,800)
(Increased) decreased net loss				$ 39,900	$ 3,400		$ 73,700	$ (5,800)
(Increased) decreased net loss per share | $ / shares				$ 0.32	$ 0.03		$ 0.60	$ (0.05)
Tests delivered in prior periods that were fully collected | Disruption at Change Healthcare
Allowances on accounts receivable				$ 1,300			$ 1,300
Amounts not refunded to insurance carriers
Increased (decreased) revenues				1,900			4,100
(Increased) decreased net loss				$ 1,900			$ 4,100
(Increased) decreased net loss per share | $ / shares				$ 0.02			$ 0.03
BGI Genomics
Revenue recognized			$ 44,000
Agreement term			10 years
Revenue, remaining performance obligation			$ 6,000
Transaction price			50,000
Contract asset				$ 4,500			$ 4,500
Other assets				3,800			3,800
Prepaid expenses and other current assets				600			600
Prepaid royalties			$ 20,000
BGI Genomics | License and related development services
Number of performance obligations | item	2
Revenue, remaining performance obligation	$ 24,000					$ 24,000
BGI Genomics | Sequencing services
Other assets											$ 6,000
BGI Genomics | Sequencing products
Other assets											4,000
BGI Genomics | Sequencing products and services
Other assets											$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized								$ 600
Revenue, remaining performance obligation									$ 20,000
Deferred revenue				18,900	$ 200		18,900	200
BGI Genomics | Equipment and Services
Equipment and services received				400	1,000		400	2,600
Foundation Medicine ("FMI")
Revenue recognized							24,300
Agreement term		5 years
Automatic renewals, successive period thereafter		1 year
Revenue, remaining performance obligation				7,700			7,700
Transaction price				32,000			32,000
Prepaid royalties				5,000			5,000
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized				200	$ 100		200	$ 400
Revenue, remaining performance obligation				5,000			5,000
Deferred revenue				$ 3,000			$ 3,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized						200
Revenue, remaining performance obligation	$ 19,300					$ 19,300